Absence of significant pharmacokinetic and pharmacodynamic interactions between artemether and quinoline antimalarials.
The study was carried out to investigate the pharmacokinetic and pharmacodynamic interactions between artemether (ARTEM) and quinoline antimalarials namely mefloquine (MQ), quinine (QN) and primaquine (PQ) when given concurrently. A randomised comparative, seven way cross-over design was performed in eight healthy male Thais following the administrations of seven drug regimens on seven occasions i.e. a single oral dose of ARTEM (300 mg), or MQ (750 mg), or QN (600 mg), or PQ (45 mg) alone, or the combination of ARTEM (300 mg) with MQ (750 mg), or QN (600 mg), or PQ (45 mg). All clinical and laboratory parameters were normal in all subjects, before, during and after the study. The eight subject experienced no adverse effect after ARTEM, QN, PQ alone regimens, or combination of ARTEM with QN and PQ. After administration of MQ in either occasion, 3 subjects had weakness, nausea, abdominal pain, and diarrhoea; one subject complained of dizziness. All symptoms were mild and occurred during the first day of MQ administration. The fitting of the concentration-time curves of ARTEM, QN and PQ, to a one-compartment model with first order absorption yielded satisfactory results in all subjects. The best fit model for MQ was two-compartment model with first order absorption. The pharmacokinetics of all investigated drug, when given alone or in combination were not significantly different.
Na-Bangchang
K
K
Pharmacology Unit, Faculty of Allied Health Sciences, Thammasat University, Pathumthani 12121, Thailand.
Karbwang
J
J
Ubalee
R
R
Thanavibul
A
A
Saenglertsilapachai
S
S
D000328:Adult; D000962:Antimalarials / Q000493:pharmacokinetics*; D000077549:Artemether; D037621:Artemisinins; D018592:Cross-Over Studies; D004347:Drug Interactions; D006801:Humans; D008297:Male; D015767:Mefloquine / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D011319:Primaquine / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D011803:Quinine / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D012717:Sesquiterpenes / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology
D000962:Antimalarials; D037621:Artemisinins; D012717:Sesquiterpenes; D011803:Quinine; D000077549:Artemether; D011319:Primaquine; D015767:Mefloquine